Refractory Ileal Perforations in a Cytomegalovirus-Infected Premature Neonate Resolved After Ganciclovir Therapy
Severe neonatal gastrointestinal diseases such as necrotizing enterocolitis or spontaneous intestinal perforation is a potentially lethal condition that predominantly occurs in premature babies. Cytomegalovirus (CMV), which is known to cause congenital and acquired infections in newborns, has also been implicated in gastrointestinal diseases such as severe in premature infants. However, the pathogenic role of CMV and the effects of antiviral therapy in severe gastrointestinal illness in premature neonates is currently unclear.
We present the baby, born at 26-weeks gestation, presented with progressive dyspepsia and abdominal distention after closure of patent ductus arteriosus symptoms on the day of life (DOL) 4, which requires emergency surgery for ileal perforation in DOL8 it. After surgery, abdominal symptoms persist and operation appeared both performed for recurrent ileal perforation in DOL17. Even after prolonged abdominal symptoms and pathological examination in the affected bowel in a second operation showed CMV inclusion bodies.
Immunoreactivity for CMV antigen was detected in specimens from the first operation on DOL8. Blood and urine CMV-DNA were detected in DOL28. CMV-DNA was also detected in umbilical cord dry obtained within a week of birth. A 6-week course of intravenous ganciclovir (12 mg / kg / day) was started in DOL34 and then the symptoms resolved together with a reduction in CMV-DNA blood. Pathologic findings characteristic of CMV was not detected in the resection specimen in DOL94 ileostomy closure.
These observations suggest that the anti-CMV therapy may be beneficial for some preterm infants with severe gastrointestinal disease related CMV and warrants further research focusing on the role of pathogens, diagnosis, treatment and prevention of this underrecognized etiology severe gastrointestinal disease, especially in premature neonates.
Refractory Ileal Perforations in a Cytomegalovirus-Infected Premature Neonate Resolved After Ganciclovir Therapy
Primary Human Cytomegalovirus Infection and Reactivation: Insights From Molecules Virion-Carried
Human cytomegalovirus (HCMV), a ubiquitous beta-herpes virus, are able to build life-long latency after initial infection. periodic reactivation occurred after immunosuppression, remains a major cause of death in immunocompromised patients. HCMV have to achieve structural balance and functional with the host at the beginning of the entry. virion-do mediators considered to play an important role in the adaptation of the virus into new cellular environment at the time of entry.
Moreover, a clear distinction between primary infection and reactivation is the idea that the virion-packaged factor has been formed so that the molecule can be used quickly by the virus. Instead, the mediator virion-do should be transcribed and translated; thus, they are not available for reactivation. Therefore, understanding the molecular virion-do help to explain HCMV reactivation. In this article, the impact of molecules on the virion-packaged virus structure, biological behavior and life cycle of the virus will be reviewed.
Description: A sandwich quantitative ELISA assay kit for detection of Human Adropin (AD) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Human Adropin (AD) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop Cytomegalovirus infections. In some patients with AIDS, the virus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of the disease. An indicator of active infection is needed to facilitate the diagnosis of cytomgalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus was detected in the leukocytes of both the peripheral blood and BALF during the early phase of the disease.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop Cytomegalovirus infections. In some patients with AIDS, the virus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of the disease. An indicator of active infection is needed to facilitate the diagnosis of cytomgalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus was detected in the leukocytes of both the peripheral blood and BALF during the early phase of the disease.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop Cytomegalovirus infections. In some patients with AIDS, the virus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of the disease. An indicator of active infection is needed to facilitate the diagnosis of cytomgalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus was detected in the leukocytes of both the peripheral blood and BALF during the early phase of the disease.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, cytomegalovirus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of cytomegalovirus disease. An indicator of active CMV infection is needed to facilitate the diagnosis of cytomegalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, cytomegalovirus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of cytomegalovirus disease. An indicator of active CMV infection is needed to facilitate the diagnosis of cytomegalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.
Description: Ten to forty percent of the patients with acquired immunodeficiency syndrome (AIDS) develop cytomegalovirus (CMV) infections. In some patients with AIDS, cytomegalovirus is detected in the bronchoalveolar lavage fluid (BALF), urine, and other specimens, even when there are no symptoms of cytomegalovirus disease. An indicator of active CMV infection is needed to facilitate the diagnosis of cytomegalovirus disease in patients with AIDS or HIV infection. Cytomegalovirus p65 antigen was detected in the leukocytes of both the peripheral blood and BALF during the early phase of CMV disease.
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It has the hygromycin selection under RSV promoter.
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It has the Zeocin selection under RSV promoter.
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the blasticidin marker under RSV promoter.
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Neomycin marker under RSV promoter.
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Puromycin marker under RSV promoter.
Cytomegalovirus Immediate Early Antigen (CMV-IE) Antibody
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the GFP-Blasticidin fusion marker under RSV promoter.
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the GFP-Puromycin fusion marker under RSV promoter.
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the RFP-Blasticidin fusion marker under RSV promoter.
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the RFP-Puromycin fusion marker under RSV promoter.
Description: CPI-169 is a novel, small molecule and potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2) [1].CPI-169 has been found to be a potent EZH2 inhibitor with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2).
Description: CPI-169 is a novel, small molecule and potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2) [1].CPI-169 has been found to be a potent EZH2 inhibitor with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2).
Description: CPI-169 is a novel, small molecule and potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2) [1].CPI-169 has been found to be a potent EZH2 inhibitor with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2).
Description: CPI-169 is a novel, small molecule and potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2) [1].CPI-169 has been found to be a potent EZH2 inhibitor with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2).
Description: CPI-169 is a novel, small molecule and potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2) [1].CPI-169 has been found to be a potent EZH2 inhibitor with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2).
Description: Qualitative indirect ELISA kit for measuring Human anti-cytomegalovirus (CMV) antibody (IgG) in samples from serum. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Human anti-cytomegalovirus(CMV) antibody (IgG) ELISA Kit
Description: Qualitative indirect ELISA kit for measuring Human anti-cytomegalovirus(CMV) antibody (IgG) in samples from serum. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Human anti-cytomegalovirus(CMV) antibody (IgM) ELISA Kit
Description: Qualitative captureELISA ELISA kit for measuring Human anti-cytomegalovirus (CMV) antibody (IgM) in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Human anti-cytomegalovirus(CMV) antibody (IgM) ELISA Kit
Description: Qualitative captureELISA ELISA kit for measuring Human anti-cytomegalovirus(CMV) antibody (IgM) in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Human Cytomegalovirus (CMV) IgG ELISA Kit (Direct EIA)
Description: Quantitative sandwich ELISA for measuring Human Cytomegalovirus Antigen (CMV Ag) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Cytomegalovirus Antigen (CMV Ag)
Description: Quantitative sandwich ELISA for measuring Human Cytomegalovirus Antigen (CMV Ag) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Cytomegalovirus Antigen (CMV Ag)
Description: Quantitative sandwich ELISA for measuring Human Cytomegalovirus Antigen (CMV Ag) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Human anti-cytomegalovirus IgG ,anti-CMV ELISA Kit
Description: Human cytomegalovirus is a species of the Cytomegalovirus genus of viruses, which in turn is a member of the viral family known as Herpesviridae or herpesviruses. It is typically abbreviated as HCMV or, commonly but more ambiguously, as CMV. CMV Virus Envelope Glycoportein B (CMV-GB) can be cleaved into glycoprotein GP55. Envelope glycoprotein that plays a role in host cell entry, cell to-cell virus transmission, and fusion of infected cells. CMV-GB may be involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. Furthermore, CMV-GB can interact with host integrin ITGB1, PDGFRA and EGFR that likely serve as postattachment entry receptors. Also, CMV-GB participates in the fusion of viral and cellular membranes leading to virus entry into the host cell. Membrane fusion is mediated by the fusion machinery composed at least of gB and the heterodimer gH/gL.
Description: Enzyme-linked immunosorbent assay kit for quantification of Human anti-cytomegalovirus (CMV) antibody ( IgG) in samples from serum, plasma, tissue homogenates and other biological fluids.
ELISA kit for Human anti-cytomegalovirus (CMV) antibody ( IgM)
Description: Enzyme-linked immunosorbent assay kit for quantification of Human anti-cytomegalovirus (CMV) antibody ( IgM) in samples from serum, plasma, tissue homogenates and other biological fluids.
Recombinant Salmonella sulA Protein (aa 1-169) (strain RKS4594)
Description: A competitive ELISA for quantitative measurement of Rat adropin(AD) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
×
Cytomegalovirus (CMV) is the most common congenital infection worldwide, and remains a significant cause of neurological deficiencies and sensory deafness in developed countries. Mrs. primary infection, reactivation or reinfection during pregnancy can cause fetal infections and congenital CMV syndrome. The purpose of this study was to analyze the seroprevalence of CMV in accordance with the demographic features of pregnant women in Western Romania as well as the evolution of CMV immunity in two intervals.
